Rom Eliaz

BioIncubator Fund c/o Interlab
South Industrial Area
18 HaKishon St.
Yavne 81220
Israel

Rom Eliaz, PhD, MBA, joined the Healthcare team as the Head of the Israel Bio-Incubator in September 2016. He has over 20 years of pharmaceutical and biotechnology development experience as a scientist, entrepreneur, executive and venture capitalist. Previously, Rom was VP of Branded Products at Teva since Sept 2012, in charge of R&D innovative drugs, and involved in commercialization, alliance management, and pipeline asset management. Prior to Joining Teva, Rom held several executive positions as the CEO of NasVax, CEO of ImmCure Therapeutics and Strategic Partner at The Colmen Group. Previously, Rom was VP of Development and Project Management at Intradigm, which was merged with Silence Therapeutics. Formerly, He was Director of Product Development and Project Management at Rinat Neuroscience, which was acquired by Pfizer in 2006. Earlier, Rom held various management positions at Alza. Following its acquisition by Johnson & Johnson in 2001, he managed J&J investment portfolio in various different pharmaceutical and biotechnology companies, led to the market several blockbuster drugs and also advanced over 10 drug candidates from discovery research to clinical trials and commercialization. Before joining the biotech industry, Rom was appointed as Assistant Professor at University of California San Francisco, schools of Medicine and Pharmacy, following a Post-Doctoral work in the fields of drug delivery, drug targeting, tissue engineering and gene therapy at UCSF.
Rom serves as a Director on the Board of Directors of Boston Therapeutics (NASDAQ: BTHE), Oxygen Therapy and advisor to Band of Angels. He received his PhD in Chemical Engineering and Biotechnology from the Weizmann Institute of Sciences and Ben-Gurion University (BGU). He also holds MSc, cum laude, in Chemical Engineering from BGU. He earned an MBA, cum laude, from Harvard Business School and Boston University program at BGU. He has published over 40 articles and hold more than 10 patents in the fields of drug delivery, gene therapy and drug targeting. Rom is based in Tel Aviv.

Portfolio Companies

more about
ARTSaVit
more about
Metabomed LTD